Sun Pharma Notes Organon Shareholder Approval for Proposed Acquisition

Sun Pharmaceutical Industries Ltd. has announced that **Organon & Co.'s shareholders have approved** the proposals related to the previously announced merger transaction. Upon completion, **Organon is expected to become a wholly owned subsidiary of Sun Pharmaceutical Holdings USA, Inc.,** an indirect wholly owned subsidiary of Sun Pharma. The shareholder approval marks a significant milestone toward completing the acquisition. However, the transaction is **still subject to customary closing conditions**, including the receipt of all applicable regulatory approvals. Sun Pharma had originally announced the proposed acquisition on **April 27, 2026**. ### Key Highlights * ✅ Organon shareholders have approved the proposed acquisition. * ✅ Organon is expected to become a wholly owned subsidiary of Sun Pharma's U.S. holding company. * ✅ The deal remains subject to regulatory approvals and other customary closing conditions. * ✅ The approval represents a key milestone toward completing the transaction. Sun Pharma is India's largest pharmaceutical company and a leading global player with operations across innovative medicines, generics, and consumer healthcare. The company has a presence in over **100 countries**, with its innovative medicines portfolio contributing around **22% of total sales**. 📌 **Disclaimer:** This post is for informational and educational purposes only and should not be construed as investment advice. Investors should conduct their own research before making any investment decisions. $SUNPHARMA